This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	LIM domain kinase 1 (LIMK1); LIMK2	<p>Studies in cell culture suggest that inhibiting LIMK1 and LIMK2 could help treat metastatic cancer. In a coculture of squamous carcinoma cells and cancer-associated fibroblasts, addition of a LIMK1 and LIMK2 inhibitor significantly decreased invasion of cells into a collagen matrix compared with addition of vehicle control ($p < 0.01$). Next steps include <i>in vivo</i> pharmacological proof-of-concept experiments.</p> <p>SciBX 3(39); doi:10.1038/scibx.2010.1176 Published online Oct. 7, 2010</p>	LIMK1 and LIMK2 inhibitors patented; available for licensing through Cancer Research Technology Ltd., the technology transfer arm of Cancer Research UK	<p>Scott, R.W. <i>et al. J. Cell Biol.</i>; published online Sept. 27, 2010; doi:10.1083/jcb.201002041</p> <p>Contact: Michael F. Olson, The Beatson Institute for Cancer Research, Glasgow, U.K. e-mail: michael.olson@glasgow.ac.uk</p>